AU2001238179A1 - Method and compositions for treating hepatocellular cancer - Google Patents

Method and compositions for treating hepatocellular cancer

Info

Publication number
AU2001238179A1
AU2001238179A1 AU2001238179A AU3817901A AU2001238179A1 AU 2001238179 A1 AU2001238179 A1 AU 2001238179A1 AU 2001238179 A AU2001238179 A AU 2001238179A AU 3817901 A AU3817901 A AU 3817901A AU 2001238179 A1 AU2001238179 A1 AU 2001238179A1
Authority
AU
Australia
Prior art keywords
compositions
hepatocellular cancer
treating hepatocellular
treating
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238179A
Inventor
Lisa H. Butterfield
James S. Economou
Antoni Ribas Bruguera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU2001238179A1 publication Critical patent/AU2001238179A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464481—Alpha-feto protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
AU2001238179A 2000-02-10 2001-02-12 Method and compositions for treating hepatocellular cancer Abandoned AU2001238179A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18196600P 2000-02-10 2000-02-10
US60/181,966 2000-02-10
US66025200A 2000-09-12 2000-09-12
US09/660,252 2000-09-12
US66250500A 2000-09-14 2000-09-14
US09/662,505 2000-09-14
PCT/US2001/004539 WO2001058922A2 (en) 2000-02-10 2001-02-12 Method and compositions for treating hepatocellular cancer

Publications (1)

Publication Number Publication Date
AU2001238179A1 true AU2001238179A1 (en) 2001-08-20

Family

ID=27391498

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238179A Abandoned AU2001238179A1 (en) 2000-02-10 2001-02-12 Method and compositions for treating hepatocellular cancer

Country Status (7)

Country Link
EP (1) EP1253930A4 (en)
JP (1) JP3876162B2 (en)
KR (1) KR100482920B1 (en)
CN (1) CN1255427C (en)
AU (1) AU2001238179A1 (en)
HK (1) HK1046853A1 (en)
WO (1) WO2001058922A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100985914B1 (en) * 2006-12-13 2010-10-08 주식회사 바이오리더스 Cell Surface Expression Vector for liver Cancer Specific Antigen Alpha-fetoprotein and Microorganism Transformed by Thereof
WO2008113970A2 (en) * 2007-03-16 2008-09-25 Ucl Business Plc Peptides
KR100900742B1 (en) * 2007-05-17 2009-06-08 크레아젠 주식회사 Animal Models Carrying Tumors Expressing Human Liver Cancer-Specific Antigen and Method for Analyzing Prevention and Treatment Efficacy of Dendritic Cells-Derived Immunotherapeutics Using the Above
US8541543B2 (en) * 2007-11-20 2013-09-24 Academia Sinica Peptides specific for hepatocellular carcinoma cells and applications thereof
JP6903587B2 (en) * 2015-04-03 2021-07-14 ユーリカ セラピューティックス， インコーポレイテッド Constructs targeting AFP peptide / MHC complexes and their use
CN113072636A (en) * 2020-01-06 2021-07-06 香雪生命科学技术（广东）有限公司 T cell receptor for identifying AFP and its code sequence
CN113321725A (en) * 2020-02-28 2021-08-31 香雪生命科学技术（广东）有限公司 T cell receptor for identifying AFP

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226551B (en) * 1988-07-29 1991-01-24 Sclavo Spa IMMUNOLOGICALLY ACTIVE SYNTHETIC PEPTIDE CAPABLE OF INDUCING THE PRODUCTION OF ANTIBODIES WITH HIGH SPECIFICITY TOWARDS ALPHA-PHETOPROTEIN AND THEIR USE IN THE DIAGNOSTIC FIELD
JPH10513347A (en) * 1995-01-24 1998-12-22 ロバート エイ． マルギタ Recombinant human α-fetoprotein and use thereof
CN1739791A (en) * 1997-02-13 2006-03-01 加利福尼亚大学董事会 Prevention and treatment of hepatocellular cancer

Also Published As

Publication number Publication date
HK1046853A1 (en) 2003-01-30
KR100482920B1 (en) 2005-04-14
JP2003522195A (en) 2003-07-22
WO2001058922A2 (en) 2001-08-16
CN1255427C (en) 2006-05-10
JP3876162B2 (en) 2007-01-31
EP1253930A2 (en) 2002-11-06
KR20020073203A (en) 2002-09-19
WO2001058922A3 (en) 2002-02-14
EP1253930A4 (en) 2003-05-21
WO2001058922A9 (en) 2002-10-17
CN1398187A (en) 2003-02-19

Similar Documents

Publication Publication Date Title
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2002219945A1 (en) Composition and method for treating snoring
AU2003230750A1 (en) Compositions and methods for treating cancer
HUP0301690A3 (en) Synergistic methods and compositions for treating cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
EP1438062A4 (en) Methods and compositions for treating dermal lesions
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
AU2003225535A1 (en) Methods and compositions for treating cancer
AU2002236626A1 (en) Compositions and methods for treating hyperpigmentation
AUPR152100A0 (en) Method for treating coral
AU2001294686A1 (en) Composition and process for treating metals
AU2001275085A1 (en) Methods, compounds and compositions for treating gout
AU2001253836A1 (en) Method of treating cancer
AU2001233932A1 (en) Method and composition
AU2001238179A1 (en) Method and compositions for treating hepatocellular cancer
AU2001218024A1 (en) Methods for treating and preventing alopecia
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
AU2001261513A1 (en) Composition and method for increasing testosterone levels
AU2003298708A1 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
AU2001238288A1 (en) Method and compositions for treating fibrotic diseases
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
AUPR644301A0 (en) Method and composition for treatment of cancer
AU2001243297A1 (en) Method for treating or preventing depression
AU1341001A (en) Composition and process for treating metals
AU2002305700A1 (en) Composition and method for treating cells